Professor, Department of Inorganic Chemistry, Montevideo, Uruguay
Received date: November 19, 2012; Accepted date: November 21, 2012; Published date: November 23, 2012
Citation: Gambino D (2012) Metal-Organic Frameworks in Nanotherapeutics: Development of Novel Drug Nanocarriers for Conventional and Nuclear Oncology. J Nanomed Biotherapeut Discov 2:e120. doi:10.4172/2155-983X.1000e120
Copyright: © 2012 Gambino D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Journal of Nanomedicine & Biotherapeutic Discovery
In the search for novel therapeutic approaches that could circumvent recognized drawbacks of conventional therapy against cancer, several systems based on nanoparticles are currently being investigated. Metalorganic frameworks (MOFs) are porous materials that result from the assembly of metal ions or inorganic clusters with polydentate organic linkers. These arrangements lead to porous structures that have been under study during the last years due to their potentiality for different technological applications, like gas storage or purification, catalysis or sensors. The selection of the metal and the linker has significant effects on the structure and properties of the MOF. In recent years these hybrid metal-organic materials have emerged as potential carrier systems for drugs due to their relevant properties for this field, like biodegradability, low toxicity, high and regular porosities, tunable pore size and connectivity, high drug loading capacity, controlled drug release and ability to prolong the drug residence time and to reduce drug toxicity. These properties can be tuned by modifying MOFs structures and porosities. Nanoscale MOFs (NMOFs) are currently under research for the selective delivery of clinical use metal-based antitumor drugs. These materials could be suitable not only as vehicles of conventional organic and metal-based antitumor drugs but also for the development of nanoparticle systems for nuclear oncology or radiotherapy.